Clinical Trials Logo

Depression clinical trials

View clinical trials related to Depression.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT04388202 Withdrawn - Clinical trials for Major Depressive Disorder

Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram

Start date: October 15, 2020
Phase: Phase 4
Study type: Interventional

The LEAP-SE study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.

NCT ID: NCT04388189 Withdrawn - Clinical trials for Major Depressive Disorder

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

Start date: October 15, 2020
Phase: Phase 4
Study type: Interventional

The LEAP-DB study will be conducted to validate the utility of EEG biomarkers as an aid to antidepressant treatment selection in adults with MDD.

NCT ID: NCT04369001 Withdrawn - Depression Clinical Trials

Program ACTIVE: Phase 2

Start date: December 2020
Phase: N/A
Study type: Interventional

The present study seeks to tailor the original Program ACTIVE (Adults Coming Together to Increase Vital Exercise) to meet the cultural norms and needs of adult Black men with comorbid Type 2 diabetes and depression by using focus groups comprised of Black men with Type 2 diabetes. The use of peer perspectives allows for an improved strategy to reach, retain, and improve outcomes in this population. Following the tailoring of program materials, the intervention (Program ACTIVE) will be facilitated with Black men with comorbid Type 2 diabetes and depression using evidence-based cognitive behavioral therapy and community-based exercise interventions.

NCT ID: NCT04317001 Withdrawn - Clinical trials for Major Depressive Disorder

Treatment for Cognitive Impairment in Depression

Start date: December 1, 2018
Phase: Phase 3
Study type: Interventional

The proposed study seeks to investigate the effects of modafinil on cognitive function in depression, which holds promise for better treating cognitive impairment in depression, as well as better understand cognitive dysfunction in MDD from a neural rather than diagnostic point of view to better classify and treat these disabling symptoms.

NCT ID: NCT04283058 Withdrawn - Depression Clinical Trials

Low Dose Ketamine Infusion for the Treatment of Resistant Depression

Start date: June 29, 2020
Study type: Observational

The purpose of this investigator-initiated observational study is to examine how low Ketamine infusion treatments impact antidepressant and anti-suicidal effects for refractory and non-refractory depression.

NCT ID: NCT04273191 Withdrawn - Clinical trials for Postpartum Depression

A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)

Start date: February 2020
Phase: Phase 4
Study type: Interventional

In this Phase 4 study, women who have been prescribed commercial ZULRESSO™ (brexanolone) by a physician as standard of care for postpartum depression (PPD) and who are planning to receive the infusion per United States Prescribing Information (USPI) at a Risk Evaluation and Mitigation Strategy (REMS)-certified healthcare center are being asked to participate to collect data on multimodal neuroimaging parameters in order to evaluate the relationship between changes in depressive symptoms and changes in neuroimaging parameters.

NCT ID: NCT04205890 Withdrawn - Depression Clinical Trials

Intravenous Ketamine Effects on Functional Neuroanatomy

Start date: May 2, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the neuroanatomical effects of ketamine treatment on patients with treatment-resistant depression. The investigators will compare the neuroimaging of patients several days before and after injection in order to assess the more durable changes induced by ketamine. In addition, changes in perfusion will be analyzed, in addition to changes in neurovascular coupling, and functional connectivity that are correlated with psychiatric measures.

NCT ID: NCT04020549 Withdrawn - Depression Clinical Trials

Single-Session Computerized Mental Health Intervention for Rural Indian Adolescents

Start date: July 31, 2019
Phase: N/A
Study type: Interventional

The overall aim of this project is to understand if single-session interventions are acceptable, culturally appropriate, and effective for Indian adolescents attending a rural, low-resource government school. The investigators will be examining the effects of a computerized intervention on the well-being and mental health of adolescents. The investigators hypothesize that the intervention will yield statistically significant improvements in wellbeing and mental health relative to a study skills control condition.

NCT ID: NCT03995914 Withdrawn - Depression Clinical Trials

Depression and Major Adverse Events in Older Patients Who Undergo a Transcatheter Aortic Valve Implantation

Start date: June 1, 2019
Study type: Observational

Depression, screened using the Geriatric Depression Scale (GDS) Short Form, has recently been found to be associated with a 3-fold increase in 1-year mortality after aortic valve replacement (AVR) in patients aged 70 or older. The main objective of the study is to evaluate whether the 1-year incidence of major adverse cardiac and cerebrovascular events (MACCEs), evaluated according to the valve academic research consortium 2 (VARC-2 criteria), in patients aged 75 or older who undergo a transcatheter aortic valve implantation (TAVI), should be similar in patients with depression systematically screened (using the 15-item GDS score), confirmed, and handled by a psychiatrist, and in patients without depression detected, after adjusting for frailty criteria and comorbidities.

NCT ID: NCT03978182 Withdrawn - Depression Clinical Trials

Accelerated Deep TMS in the Elderly Depressed: A Brain Imaging Approach

Start date: June 2019
Phase: N/A
Study type: Interventional

With a growing number of elderly persons, geriatric depression - associated with important morbidity and mortality- is becoming a significant health problem. Given the risk of polypharmacy and increased side effects, alternative non pharmaceutical treatments such as repetitive transcranial magnetic stimulation (rTMS) may be a solution. Given recent positive results with accelerated rTMS in the elderly depressed, it is of interrest to continue to develop promising non-invasive treatment stimulations. The FDA approved deep brain TMS (dTMS) technique may be a promising option, targeting the brain underneath the neocortex with potentially better response and remission rates. Therefore, in a sham-controlled cross-over fashion, the investigators will treat 44 geriatric depressed patients with accelerated dTMS (5 sessions/day over 4 days only), and evaluate clinical efficacy and safety. Because new introduced rTMS paradigms should be rigorously neurobiologically examined before applying them on a regular basis, this research will include multimodal brain imaging techniques to elucidate the working mechanisms of this application in order to optimize treatment for such populations.